Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know

Abstract

Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a causal role in the de-velopment of atherosclerotic cardiovascular disease risk. However, guidelines and consensus statement recom-mendations vary regarding how clinicians should incorporate Lp(a) into patient care. To provide practical answers to key questions pertaining to Lp(a) that clinicians will find useful when assessing and treating patients, a global think tank was convened. Representatives from seven national and international stakeholder organiza-tions answered questions that were focused on: Lp(a) measurement; ethnic, gender, and age considerations; fac-toring Lp(a) into risk assessment; and current and emerging treatment options for elevated Lp(a). This manuscript summarizes the finding from this global think tank. Areas requiring further investigation were iden-tified, and the need to standardize reporting of Lp(a) levels to ensure harmonization and comparability across laboratories and research studies is emphasized.(c) 2022 The Authors.